Drug Trial Radar · NCT07635563
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 21, 2026
Primary completion
Apr 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Incannex Healthcare LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized, double-blind, multi-dose crossover clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive sleep apnea. The primary endpoint is: Change in AHI4 at the end of each treatment period compared to baseline (each treatment period is 28 days). The study will consist of three separate four-way crossover dose-comparison studies each comparing three dose strengths of IHL-42X to placebo. The double-blind four-way crossover will be conducted according to a Williams design. Each of the crossover studies will test different doses of dronabinol in combination with a distinct, set dose of acetazolamide. In total, nine different combinations of dronabinol and acetazolamide formulated as IHL-42X will be tested in the study. The optimal dose strength will be selected based on safety and efficacy over a 4-week treatment period.
Conditions
- Obstructive Sleep Apnea (OSA)
Interventions
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamideDrug
DReAMzz Phase 2 Investigational Product - IHL-42X Dose 1
IHL-42X: 5 mg dronabinol + 125 mg acetazolamideDrug
DReAMzz Phase 2 Investigational Product - IHL-42X Dose 2
IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamideDrug
DReAMzz Phase 2 Investigational Product - IHL-42X Dose 3
IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamideDrug
DReAMzz Phase 2 Investigational Product - IHL-42X Dose 4
IHL-42X: 5 mg dronabinol + 250 mg acetazolamideDrug
DReAMzz Phase 2 Investigational Product - IHL-42X Dose 5
IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamideDrug
DReAMzz Phase 2 Investigational Product - IHL-42X Dose 6
IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamideDrug
DReAMzz Phase 2 Investigational Product - IHL-42X Dose 7
IHL-42X: 5 mg dronabinol + 375 mg acetazolamideDrug
DReAMzz Phase 2 Investigational Product - IHL-42X Dose 8
IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamideDrug
DReAMzz Phase 2 Investigational Product - IHL-42X Dose 9
Placebo: Negative controlDrug
DReAMzz Phase 2 Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in AHI4 at the end of each treatment period compared to baselineTime frame: Each treatment period (28 days)
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Exalt Clinical Research
Chula Vista, California · Recruiting
Teradan Clinical Trials LLC
Brandon, Florida · Recruiting
CNS Healthcare - Jacksonville
Jacksonville, Florida · Recruiting
CNS Healthcare Orlando
Orlando, Florida · Recruiting
Palm Beach Research Center
West Palm Beach, Florida · Recruiting
Tandem Clinical Research
Marrero, Louisiana · Not yet recruiting
Velocity Clinical Research, Rockville
Rockville, Maryland · Recruiting
CTI Clinical Research Center
Cincinnati, Ohio · Recruiting
Intrepid Research
Cincinnati, Ohio · Recruiting
Velocity Clinical Research, Anderson
Anderson, South Carolina · Recruiting
CNS Healthcare - Memphis
Memphis, Tennessee · Recruiting
FutureSearch Trials of Dallas
Dallas, Texas · Recruiting
Sleep Therapy & Research Center
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.